Detection of PSMA expression on circulating tumor cells by blood-based liquid biopsy in prostate cancer
DOI:
https://doi.org/10.33393/jcb.2024.2636Keywords:
Circulating tumor cells, Liquid biopsy, mCRPC, Prostate-specific membrane antigen (PSMA)Abstract
Background: For patients with mCRPC, PSMA-targeted radioligand treatment has significantly improved the clinical outcome. A blood-based liquid biopsy assay for recognizing PSMA protein expression on circulating tumor cells may be beneficial for better informing therapeutic decision-making and identifying the patients most likely to benefit from PSMA-targeted radioligand therapy.
Methods: Using high-throughput imaging and digital AI pathology algorithms, a four-color immunofluorescence assay has been developed to find PSMA protein expression on CTCs on a glass slide. Cell line cells (LNCaP/PC3s/22Rv1) spiked into healthy donor blood were used to study the precision, specificity, sensitivity, limit of detection, and overall accuracy of the assay. Clinical validation and low-pass whole-genome sequencing were performed in PSMA-PET-positive patients with high-risk mCRPC (N = 24) utilizing 3 mL of blood.
Results: The PSMA CTC IF assay achieved analytical specificity, sensitivity, and overall accuracy above 99% with high precision. In the clinical validation, 76% (16/21) of the cases were PSMA positive with CTC heterogeneity, and 88% (21/24) of the patients contained at least one conventional CTC per milliliter of blood. Thirty-six low-pass-sequenced CTCs from 11 individuals with mCRPC frequently exhibited copy number increases in AR and MYC and losses in RB1, PTEN, TP53, and BRCA2 locus.
Conclusions: The analytical validation utilizing Epic Sciences’ liquid biopsy CTC platform demonstrated the potential to detect PSMA protein expression in CTCs from patients with mCRPC. This assay is positioned as an effective research tool to evaluate PSMA expression, heterogeneity, and therapeutic response in many ongoing clinical studies to target tumors that express PSMA.
Downloads
References
Bakht MK, Derecichei I, Li Y, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2018;26(2):131-146. https://doi.org/10.1530/ERC-18-0226 PMID:30400059 DOI: https://doi.org/10.1530/ERC-18-0226
Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018;215(1):159-175. https://doi.org/10.1084/jem.20171052 PMID:29141866 DOI: https://doi.org/10.1084/jem.20171052
Zaman MU, Fatima N, Zaman A, Sajid M, Zaman U, Zaman S. Diagnostic challenges in prostate cancer and 68Ga-PSMA PET imaging: a game changer? Asian Pac J Cancer Prev. 2017;18(10):2625-2628. PMID:29072055
Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. https://doi.org/10.1056/NEJMoa2107322 PMID:34161051 DOI: https://doi.org/10.1056/NEJMoa2107322
Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate. 2000;45(4):350-354. https://doi.org/10.1002/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO;2-U PMID:11102961 DOI: https://doi.org/10.1002/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO;2-U
Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Australas Med J. 1869;14:146-149.
Armstrong AJ, Luo J, Nanus DM, et al. Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic castration-resistant prostate cancer. JCO Precis Oncol. 2020;4:PO.20.00200. https://doi.org/10.1200/po.20.00200 PMID: 33154984 DOI: https://doi.org/10.1200/PO.20.00200
Deng Z, Wu S, Wang Y, Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 2022;83:104237. https://doi.org/10.1016/j.ebiom.2022.104237 PMID:36041264 DOI: https://doi.org/10.1016/j.ebiom.2022.104237
Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14(9):623-631. https://doi.org/10.1038/nrc3820 PMID:25154812 DOI: https://doi.org/10.1038/nrc3820
Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213-3221. https://doi.org/10.1200/JCO.2007.15.8923 PMID:18591556 DOI: https://doi.org/10.1200/JCO.2007.15.8923
de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302-6309. https://doi.org/10.1158/1078-0432.CCR-08-0872 PMID:18829513 DOI: https://doi.org/10.1158/1078-0432.CCR-08-0872
Boudadi K, Suzman DL, Anagnostou V, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget. 2018;9(47):28561-28571. https://doi.org/10.18632/oncotarget.25564 PMID:29983880 DOI: https://doi.org/10.18632/oncotarget.25564
De Bono JS, Pantel K, Efstathiou E, et al. CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial. J Clin Oncol. 2021;39(6_suppl):161. https://doi.org/10.1200/JCO.2021.39.6_suppl.161 DOI: https://doi.org/10.1200/JCO.2021.39.6_suppl.161
Armstrong AJ, Halabi S, Luo J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY Study. J Clin Oncol. 2019;37(13):1120-1129. https://doi.org/10.1200/JCO.18.01731 PMID:30865549 DOI: https://doi.org/10.1200/JCO.18.01731
Greene SB, Dago AE, Leitz LJ, et al. Chromosomal instability estimation based on next generation sequencing and single cell genome wide copy number variation analysis. PLoS One. 2016;11(11):e0165089. https://doi.org/10.1371/journal.pone.0165089 PMID:27851748 DOI: https://doi.org/10.1371/journal.pone.0165089
Armstrong AJ, Gupta S, Healy P, et al. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. PLoS One. 2019;14(5):e0216934. https://doi.org/10.1371/journal.pone.0216934 PMID:31136607 DOI: https://doi.org/10.1371/journal.pone.0216934
Hamid A, Hofman MS, Bressel M, et al. Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2022;40(16_suppl):5027. https://doi.org/10.1200/JCO.2022.40.16_suppl.50 DOI: https://doi.org/10.1200/JCO.2022.40.16_suppl.5027
Lu D, Krupa R, Harvey M, et al. Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer. J Circ Biomark. 2020 Oct 23;9:13-19. PubMed:33717359 DOI: https://doi.org/10.33393/jcb.2020.2163
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Santosh Gupta, Luisa Fernandez, David Bourdon, Anis A Hamid, Anupama Pasam, Ernest Lam, Rick Wenstrup, Shahneen Sandhu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2024-01-08
Published 2024-02-21